DSpace About DSpace Software 日本語

01 奈良県立医科大学 >
012 大学院 >
0122 学位請求論文 >
01221 博士論文(医学) >
2021年度 >

Please use this identifier to cite or link to this item: http://hdl.handle.net/10564/4023

Title: Correlation of MTAP Immunohistochemistry With CDKN2A Status Assessed by Fluorescence In Situ Hybridization and Clinicopathological Features in CNS WHO Grade 2 and 3 Meningiomas: A Single Center Cohort Study.
Other Titles: CNS WHO Grade 2 および Grade 3 髄膜腫における、MTAP免疫組織化学とFISH解析によるCDKN2Aコピー数および臨床病理学的特徴との相関性
Authors: Sasaki, Shoh
Takeda, Maiko
Hirose, Takanori
Fujii, Tomomi
Itami, Hiroe
Uchiyama, Tomoko
Morita, Kohei
Matsuda, Ryosuke
Yamada, Shuichi
Nakagawa, Ichiro
Ohbayashi, Chiho
Keywords: CDKN2A homozygous deletion
Fluorescence in situ hybridization (FISH)
Spatial and temporal heterogeneity
Issue Date: Feb-2022
Publisher: Oxford University Press
Citation: Journal of neuropathology and experimental neurology Vol.81 No.2 p.117-126 (2022 Feb)
Abstract: CDKN2A homozygous deletion has occasionally been reported in atypical and anaplastic meningiomas and is considered as one of the genetic alterations commonly involved in their recurrence and malignant progression. Methylthioadenosine phosphorylase (MTAP) immunohistochemistry is a promising surrogate marker for CDKN2A homozygous deletion in different cancers but has not been examined in meningiomas. We performed CDKN2A FISH and MTAP immunohistochemistry on specimens from 30 patients with CNS WHO grade 2 (n = 27) and 3 (n = 3) meningiomas, including specimens from primary and recurrent tumors and then determined whether MTAP immunohistochemistry correlated with CDKN2A homozygous deletion and clinicopathological features. CDKN2A homozygous deletion was detected in 12% (3/26) of CNS WHO grade 2 and 67% (2/3) of CNS WHO grade 3 meningiomas; 3 cases exhibited temporal and/or spatial heterogeneity. MTAP loss was in excellent concordance with CDKN2A homozygous deletion (sensitivity; 100%, specificity; 100%). MTAP loss/CDKN2A homozygous deletion correlated with cellular proliferation (mitotic rate; p = 0.001, Ki-67 labeling index; p = 0.03) and poor prognosis (overall survival; p = 0.01, progression free survival; p < 0.001). Thus, MTAP immunostaining can be a surrogate marker for CDKN2A homozygous deletion in meningiomas, and MTAP loss/CDKN2A homozygous deletion may be an important prognostic factor for meningiomas.
Description: 博士(医学)・甲第840号・令和4年3月15日
© 2021 American Association of Neuropathologists, Inc. All rights reserved.
This is a pre-copyedited, author-produced version of an article accepted for publication in Journal of neuropathology and experimental neurology following peer review. The version of record "Vol.81 issue 2 p.117-126 (2022 Jan 29)" is available online at: https://doi.org/10.1093/jnen/nlab127.
URI: http://hdl.handle.net/10564/4023
ISSN: 00223069
DOI: https://doi.org/10.1093/jnen/nlab127
Academic Degrees and number: 24601A840
Degree-granting date: 2022-03-15
Degree name: 博士(医学)
Degree-granting institutions: 奈良県立医科大学
Appears in Collections:2021年度

Files in This Item:

File Description SizeFormat
01甲840本文の要旨.pdf甲840本文の要旨1.37 MBAdobe PDFView/Open
02甲840審査要旨.pdf甲840審査要旨223.39 kBAdobe PDFView/Open
03甲840本文.pdf甲840本文2.02 MBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.


Valid XHTML 1.0! DSpace Software Copyright © 2002-2010  Duraspace - Feedback